Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Badalona, Spain.
Motility and Functional Gut Disorders Unit, University Hospital Germans Trias i Pujol, Badalona, Spain.
Neurogastroenterol Motil. 2020 Feb;32(2):e13762. doi: 10.1111/nmo.13762. Epub 2019 Nov 22.
Chronic constipation is a common disorder with a reported prevalence ranging from 3% to 27% in the general population. Several management strategies, including diagnostic tests, empiric treatments, and specific treatments, have been developed. Our aim was to develop European guidelines for the clinical management of constipation.
After a thorough review of the literature by experts in relevant fields, including gastroenterologists, surgeons, general practitioners, radiologists, and experts in gastrointestinal motility testing from various European countries, a Delphi consensus process was used to produce statements and practical algorithms for the management of chronic constipation.
Seventy-three final statements were agreed upon after the Delphi process. The level of evidence for most statements was low or very low. A high level of evidence was agreed only for anorectal manometry as a comprehensive evaluation of anorectal function and for treatment with osmotic laxatives, especially polyethylene glycol, the prokinetic drug prucalopride, secretagogues, such as linaclotide and lubiprostone and PAMORAs for the treatment of opioid-induced constipation. However, the level of agreement between the authors was good for most statements (80% or more of the authors). The greatest disagreement was related to the surgical management of constipation.
European guidelines on chronic constipation, with recommendations and algorithms, were developed by experts. Despite the high level of agreement between the different experts, the level of scientific evidence for most recommendations was low, highlighting the need for future research to increase the evidence and improve treatment outcomes in these patients.
慢性便秘是一种常见疾病,普通人群的患病率为 3%至 27%。已经开发了几种管理策略,包括诊断测试、经验性治疗和特定治疗。我们的目的是为慢性便秘的临床管理制定欧洲指南。
在相关领域的专家(包括胃肠病学家、外科医生、全科医生、放射科医生和胃肠道动力测试专家)对文献进行彻底审查后,使用 Delphi 共识过程生成了用于慢性便秘管理的陈述和实用算法。
经过 Delphi 流程,最终达成了 73 项最终陈述。大多数陈述的证据水平较低或非常低。仅对肛门直肠测压作为肛门直肠功能综合评估以及渗透性泻药(尤其是聚乙二醇)、促动力药物普芦卡必利、促分泌剂(如利那洛肽和鲁比前列酮)和 PAMORAs 治疗阿片类药物引起的便秘的治疗达成了较高的证据水平。然而,大多数陈述的作者之间的一致性很好(80%或以上的作者)。最大的分歧与便秘的手术治疗有关。
慢性便秘的欧洲指南,包括建议和算法,是由专家制定的。尽管不同专家之间的高度一致,但大多数建议的科学证据水平较低,突出表明需要进一步研究,以增加这些患者的证据并改善治疗结果。